High ESA & Iron Doses Significantly Increase Mortality Risk In Dialysis Patients



Many patients have to contend with taking IV Iron Replacement and Erythropoiesis-Stimulating Agents (ESAs) in order to build their energy levels to avoid feeling completely drained while trying to enjoy life best they can despite Kidney Failure, Anemia (caused by a shortage of iron in a patient's body), and Dialysis. However, they do so at a great risk since high doses of ESAs, as well as Traditional Iron, are associated with significantly higher risks for Cardiovascular Disease and death among patients conducting Hemodialysis, researchers reported at the American Society of Nephrology's conference in New Orleans. With that, what can Dialysis patients do to protect themselves while improving their quality of life without compromising their longevity?

Recommended Reading: Current Anemia Management Practices May Put Chronic Kidney Disease Patients At Severe Health Risk

What's worse is that higher doses of Iron are associated with a "significantly higher risk of Cardiovascular Disease, regardless of ESA dose," according to Renal&Urology News. To be more specific, Lead Researchers, Dr. Takahiro Kuragano and Dr. Takeshi Nakanishi, found that there was no significant difference in Cardiovascular Disease risk between low ESA/low iron and high ESA/low iron. However, High ESA/high iron and even low ESA/high iron were associated with a significant 2.6 times and 3.1 times higher risk of Cardiovascular Disease. Unfortunately, in addition, high ESA/high iron was associated with a significant 2.8 times higher risk of death compared with low ESA/low iron.

Recommended Reading: The Most Important Nutrient Overlooked By CKD Patients That Can Correct Many Of Their Problems

Now, what can patients do? First, let's be clear: It is not recommended that patients stop taking or begin refusing their prescribed Iron or ESA dosages. Instead, print this article (or ask a family member or friend to print the article) and present it to your Nephrologist. Ask him/her for Triferic which is a newly FDA Approved Iron Replacement Therapy that corrects many of the issues of traditional and currently used Iron medication options. 

Recommended Reading: New Changes To Guidelines For Anemia Will Impact EPO Treatment In Chronic Kidney Disease Patients

Triferic is by most accounts safer than traditional Iron Therapies, offers patients more energy, fewer side effects, and in many cases likely improved longevity. Just take a look at what Charlene (dialysis patient) had to say about her experience with Triferic (click here to watch Charlene's video).

Recommended Reading: A New Way For Chronic Kidney Disease Patients Conducting Dialysis To Treat Anemia

What are your thoughts about current Anemia Treatments? Would you ask your Nephrologist about Trieferic? Share your thoughts and insights with the over 67,000 Friends who have liked KidneyBuzz.com on Facebook (click here). Also, follow the over 250,000+ monthly viewers who visit KidneyBuzz.com regularly for the latest daily news and information which teach those with Chronic Kidney Disease, Dialysis, Kidney Transplant, Diabetes, and Hypertension how to better manage and improve their lives. Erica Ashley Jenkins (Dialysis Nurse) said, "Hello I just wanted to let you know I work in a dialysis clinic and over half of our clinic reads this page, we enjoy everything you put on and love to have new information. My patients are very grateful."

Most Popular Stories: